Esra Aydın
A5068951908- Breast Cancer Treatment Studies
- Cancer-related Molecular Pathways
- Advanced Breast Cancer Therapies
- BRCA gene mutations in cancer
- Metastasis and carcinoma case studies
- HER2/EGFR in Cancer Research
- Nutrition, Genetics, and Disease
- Ovarian function and disorders
- Global Cancer Incidence and Screening
- Ottoman and Turkish Studies
- Cancer Immunotherapy and Biomarkers
- Urologic and reproductive health conditions
- Genetic factors in colorectal cancer
- COVID-19 and healthcare impacts
- Testicular diseases and treatments
- Genetics, Bioinformatics, and Biomedical Research
- Economic and Financial Impacts of Cancer
- Cancer Treatment and Pharmacology
- Male Breast Health Studies
- Intraperitoneal and Appendiceal Malignancies
- Monoclonal and Polyclonal Antibodies Research
- Turkish Urban and Social Issues
- Cancer Cells and Metastasis
- Ovarian cancer diagnosis and treatment
- Cancer Risks and Factors
Recep Tayyip Erdoğan University
2023-2025
Karadeniz Technical University
2024
Istanbul University
2022-2024
SUMMARY OBJECTIVE: Breast cancer is the most common type among women. One of important parameters in prognosis patients response to neoadjuvant chemotherapy. The parameter for chemotherapy success appropriate patient selection. We investigated effect tumor-stroma and ratio on response, using Residual Cancer Burden scoring systems. METHODS: Patients diagnosed with breast carcinoma core needle biopsy materials between 2010 2023 whose treatments surgeries were performed our institution scanned...
Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase as the first-line standard-of-care for patients hormone receptor-positive, HER2-negative metastatic breast cancer.
Abstract Aim of the present analysis is to compare impact antihormonal therapy versus cytotoxic chemotherapy a watch wait approach on disease-free survival (DFS) in adjuvant setting patients who underwent complete cytoreductive surgery(CRS) for recurrent adult type granulosa cell tumours ovary (GCT). Moreover, we wished identify prognostic risk factors recurrence. We included GCT-patients CRS resulting total macroscopic tumour clearance, treated two gynaecological cancer centres over 20-year...
The study is aimed to determine the relationship between delivery and breastfeeding history of patients andthe clinicopathological properties breast cancer.Materials methods: A questionnaire was utilized for study, which included age diagnosis, number children at thetime children, period each child.Results: 828 patients. median diagnosis 47 years parous women 42 nonparouswomen (p < 0.001). tumor size diagnosed within significantly larger compared theother Estrogen progesterone receptor...
The HER-2 status of breast cancer (BC) has been classified as negative or positive for a long time. Given the efficacy novel anti-HER2-targeted antibody drug conjugates (ADCs) in HER2-low BC, distinct subgroup tumors emerged within BC. biology and prognostic impact expression are not yet well defined, inconsistent results were reported. This study aims to evaluate low on response neoadjuvant chemotherapy (NACT) disease- free survival (DFS) rates.
The studies evaluating the impact of Her2 levels in neoadjuvant setting have conflicting data. aim study was to evaluate prognostic status early triple negative breast cancer(TNBC). In TNBC patients who were treated with chemotherapy (NAC) and surgery analyzed retrospectively. primary analyze status(Her2-0 Her2-low) on pathological complete response (pCR). secondary objectives disease free survival (DFS) overall (OS). 620 female cancer evaluated. 427 (68.9%) had Her2-0 193(31.1%) her2-low...
Highly selective inhibitors of cyclin-dependent kinase 4 and 6 (CDK4/6is) have emerged as a standart care for first- second-line therapies in combination with endocrine therapy (ET) HR+/HER2- metastatic breast cancer (MBC) patients. It has been reported that is more effective than ET alone safe elderly patients well young Nevertheless, very old HR+/HER2-MBC treated CDK4/6 inhibitor (CDK4/6i) combinations are relatively underrepresented randomized controlled trials. To contribute to the...
Aim: The COVID-19 pandemic has caused delays in breast cancer screening and diagnostic procedures. aim of this research was to compare the status screenings newly diagnosed cases during compared pre-pandemic period.
 Material method: This retrospective study included patients with mammography, imaging-guided biopsies, from March 2020– February 2021 (during-COVID-19) were 2019–February 2020 (pre-COVID-19). We numbers distribution over time mammography biopsies between periods. In group;...
Introduction: Breast cancer consists huge amount of the cancerrelated death in population. Ovarian is second most frequent seen type gynecological and has highest mortality among cancers since cases are detected late. The current study intended to determine prevalence oncogene mutations, especially BRCA1 BRCA2, high-risk patients diagnosed with ovarian breast Black Sea region our country. Material method: Between August 2017 January 2022, a total 223 individuals who applied center met...
Published studies on male breast cancer (MBC) and BRCA mutations are scarce usually include, a small number of patients. The clinicopathological characteristics mutant wild-type MBC patients were compared in more than forty this study.A retrospective review patients' clinical histopathological data was conducted. To compare the characteristics, chi-square test Fisher's Exact utilized. Kaplan-Meier analysis used to examine survival analysis.In total 43 cases reviewed. average duration...